Fredman E, Icht O, Moore A, Bragilovski D, et al. SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer. BMC Cancer 2024;24:431.
PMID: 38589860